Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaukosGKOS +0.59%77 Intrinsic Value: Projected FCF is $-0.72 as of Aug. 18, 2026. GuruFocus rates GKOS with a GF Score™ of 77/100 and a GF Value™ of $149.70 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 402 Medical Devices & Instruments companies, Glaukos ranks worse than 248755.97% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-18), Glaukos's Intrinsic Value: Projected FCF is $-0.72. The stock price of Glaukos is $185.62. Therefore, Glaukos's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Glaukos's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Glaukos was 277.32. The lowest was 2.58. And the median was 9.01.
GKOS's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.52 * Ranked among companies with meaningful Price-to-Projected-FCF only.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Glaukos's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
185.62
/
-0.71727986024929
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos Intrinsic Value: Projected FCF Related Terms
Glaukos Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Glaukos's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs BRKR, BIO, GMED: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Glaukos's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Glaukos's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $-0.72 mean?
Glaukos (GKOS) has a Intrinsic Value: Projected FCF of $-0.72 as of Aug. 18, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Glaukos and its competitors. Over the past decade, Glaukos' Intrinsic Value: Projected FCF has ranged from 2.58 to 277.32. According to the industry distribution chart, Glaukos ranks #999999 out of 402 companies in the Medical Devices & Instruments industry.
Is Glaukos' Intrinsic Value: Projected FCF too high?
Glaukos' current Intrinsic Value: Projected FCF is $-0.72. Over the past 10 years, this metric has ranged from a low of 2.58 to a high of 277.32. Based on the distribution chart, Glaukos ranks #999999 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Glaukos has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Intrinsic Value: Projected FCF compare to BRKR and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #999999 out of 402 companies for Intrinsic Value: Projected FCF. This places Glaukos in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.52. Historically, Glaukos' own Intrinsic Value: Projected FCF has ranged from 2.58 to 277.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.52, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Intrinsic Value: Projected FCF is $-0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $149.70, compared to a current price of $185.62 — trading 24% above its estimated fair value. The current Intrinsic Value: Projected FCF is $-0.72. Glaukos' overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Glaukos (GKOS), the current Intrinsic Value: Projected FCF is $-0.72 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $185.62 is trading 24% above its estimated GF Value™ of $149.70.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
Intrinsic Value: Projected FCF: $-0.72
GF Value™: $149.70 vs. price of $185.62 (24% above fair value)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
77GF Score
Get the complete analysis for GKOS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
